Abbvie Inc

+2.33 (+1.74%)
4:42:59 PM EDT: $135.73 -0.12 (-0.09%)

U.S. FDA Approves Rinvoq To Treat Adults And Children 12 Years And Older With Refractory, Moderate To Severe Atopic Dermatitis

Published: 01/14/2022 19:46 GMT
Abbvie Inc (ABBV) - U.S. FDA Approves Rinvoq® (upadacitinib) to Treat Adults and Children 12 Years and Older With Refractory, Moderate to Severe Atopic Dermatitis.
Abbvie - Rinvoq Approval of Two Dose Strengths Supported by Efficacy, Safety Data From Registrational Phase 3 Programs in Atopic Dermatitis.